Neuronetics announced that additional payors have updated their TMS, transcranial magnetic stimulation, coverage to reduce access barriers for patients with major depressive disorder, MDD. This expanded access allows people to receive treatment such as the Company’s NeuroStar TMS Therapy earlier in their treatment regimen. Effective immediately, BlueCross BlueShield of North Carolina has expanded its TMS policy to cover adolescents 15 years and older, based on recent clearance from the United States Food and Drug Administration for NeuroStar as the first and only TMS treatment authorized for this population. BCBC of North Carolina policies affect more than 2.2 million covered lives. Additionally, Louisiana Medicaid has started covering TMS for adults 18 and older, effective immediately.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on STIM:
- Expanded Health Policies Enhance TMS Therapy Access for Adolescents and Adults
- Neuronetics releases softwaare upgrades to elevate patient care
- NeuroStar® Releases Software Upgrades to Elevate Patient Care
- Neuronetics honors Suicide Prevention Month
- Neuronetics announces two-year anniversary of NeuroStar University